Merus B.v.

This study tests a new drug called petosemtamab against standard treatments for people with advanced head and neck cancer that has spread or come back. About 600 adults whose cancer worsened after standard therapies will be randomly assigned to receive either petosemtamab or anot…

This study tests whether adding a new drug called petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in people with advanced non-small cell lung cancer. About 180 adults who have not had prior treatment will receive the combination. The goal is to see if m…

This study tests whether adding the experimental drug petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer or shrink their tumors. About 700 adults whose cancer has spread or returned and whose tumors have a specific…